ivig multiple sclerosis
A statistically significant difference between groups of P03 was reached after 8 months. A derivative of donated blood this medicine is made by filtering antibodies from many donors and pooling them together in a. 2 1 The authors cite other reports in which IVIG benefit in RRMS was insufficient to recommend it as first-line treatment 1 I suggest that the answer is flowing in the vein. . Despite initial positive indications these treatments have been mostly disappointing. A potential treatment effect ofIVIg in MS could be mediated by several mecha-nisms as IVIg is able to modulate the immuneresponse in different ways. Intravenous immunoglobulin IVIg a therapeutic preparation of normal human polyclonal. Reduction of inflammation inhibition of macrophages and promotion of remyelination. Measure every 2-3 months if switching from IV to SC IG. Fazekas et al. Currently available disease-modifying drugs have neit...